Insider Trading

Notable insider buying and selling activity across public companies.

Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.

Articles

13,303 total articles

...', 'subtitle': '...', 'article': '...', 'image_prompt': '...', 'news_wire_title': '...', 'sentiment': '...', 'impact': '...', 'ticker': '...', 'tickers': '...', 'ticker_sentiment': '...'}

...', 'subtitle': '...', 'article': '...', 'image_prompt': '...', 'news_wire_title': '...', 'sentiment': '...', 'impact': '...', 'ticker': '...', 'tickers': '...', 'ticker_sentiment': '...'}

Halozyme Therapeutics director Mahesh Krishnan executed a $547,800 sale of common stock in late June 2026, following the exercise of stock options. The transaction occurred as the company's shares traded near their 52-week high, reflecting a strong 48% annual return. Concurrently, Halozyme announced leadership updates and confirmed minimal long-ter…

PTC Therapeutics Executive Sells Shares Amid Strong Analyst Outlook

PTC Therapeutics Executive Sells Shares Amid Strong Analyst Outlook

Neil Gregory Almstead, Chief Technical Operations Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), executed a sale of $693,151 worth of company stock on June 26, 2026. The transactions were facilitated through a Rule 10b5-1 trading plan adopted in November 2025, involving the exercise of stock options at $38.10 per share. The sale coincides with PT…

908 Devices CEO Divests $25,433 in Pre-Arranged Stock Sale

908 Devices CEO Divests $25,433 in Pre-Arranged Stock Sale

Kevin J. Knopp, President and Chief Executive Officer of 908 Devices Inc. (NASDAQ:MASS), executed a sale of 2,798 shares of the company's common stock on June 26, 2026. The transaction, valued at $25,433, was facilitated through a Rule 10b5-1 trading plan established by Mr. Knopp on May 20, 2025. The weighted average price for the sold shares was $…

Eos Energy CLO Executes $88K Stock Sale Under Pre-Arranged Plan

Eos Energy CLO Executes $88K Stock Sale Under Pre-Arranged Plan

Michael W. Silberman, serving as the Chief Legal Officer for Eos Energy Enterprises, Inc., executed a sale of 14,998 shares of common stock on June 30, 2026. The transaction, valued at $88,038, was conducted under a Rule 10b5-1 trading plan established on September 15, 2025. This plan was originally adopted to manage estimated tax withholding oblig…

Vicor Chairman and CEO Patrizio Vinciarelli Executes $3.2 Million Stock Sale Under Pre-Arranged Plan

Vicor Chairman and CEO Patrizio Vinciarelli Executes $3.2 Million Stock Sale Under Pre-Arranged Plan

Vicor Corp (NASDAQ:VICR) Chairman and Chief Executive Officer Patrizio Vinciarelli has sold approximately $3.2 million worth of company stock. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan established in February 2026. The sales coincide with a period of significant stock price appreciation and strong recent financial…

Alphabet Director Frances Arnold Executes Pre-Arranged Share Sale

Alphabet Director Frances Arnold Executes Pre-Arranged Share Sale

Alphabet Inc. director Frances Arnold executed a sale of 112 Class C shares on June 30, 2026, generating proceeds of $39,343. The transaction, conducted under a Rule 10b5-1 trading plan adopted in August 2025, reduces her direct holdings to 18,833 shares. The sale occurs as Alphabet's stock trades near $357, with analyst commentary noting valuation…